The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.
-
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Top 5 Upgrades:
-
Deutsche Bank upgraded Palo Alto Network (PANW) to Buy from Hold with a price target of $220, up from $200. With the stock underperforming the broader cyber space by 15% year-to-date, investor concerns for Palo Alto are overblown, the firm tells investors in a research note.
-
BofA upgraded Lumentum (LITE) to Neutral from Underperform with a price target of $135, up from $78. Lumentum is refocusing back to its best-of-breed optical component roots while prudently managing its lower margin optical transceiver mix under its relatively new CEO, the firm tells investors.
-
JPMorgan upgraded Capri Holdings (CPRI) to Overweight from Neutral with a price target of $30, up from $24, after meeting with the company. Capri highlighted revenue improvement throughout fiscal 2026 and a growth inflection at Michael Kors in fiscal 2027, the firm tells investors in a research note.
-
Barclays upgraded Corteva (CTVA) to Overweight from Equal Weight with a price target of $84, up from $75. The firm sees the company benefiting from solid acreage growth in Latin America. Corteva’s cost savings and innovation are boosting its profitability, the firm says.
-
Goldman Sachs double upgraded CACI (CACI) to Buy from Sell with a price target of $544, up from $407. The firm views CACI as the best positioned in the defense space under the Trump administration.
Top 5 Downgrades:
-
Oppenheimer downgraded C3 AI (AI) to Perform from Outperform without a price target. The company announced “extremely weak” preliminary fiscal Q1 results which imply a 35% sequential revenue decline, the firm tells investors in a research note.
-
Keefe Bruyette downgraded Opendoor Technologies (OPEN) to Underperform from Market Perform with a $1 price target after its Q2 earnings miss. High retail interest may continue to support valuation, but the firm is downgrading the shares on expectation of widening losses in the second half of the year, coupled with uncertainty from the strategy pivot to weigh on the shares, which trade near the high end of historical multiples.
-
Jefferies downgraded On Holding (ONON) to Underperform from Hold with a price target of $40, down from $50. The firm believes 2025 will represent the company’s peak sales growth rate.
-
Morgan Stanley downgraded Insmed (INSM) to Equal Weight from Overweight with a price target of $126, up from $112. The firm believes Insmed’s current valuation largely captures the drug’s near-term opportunity.
-
Wells Fargo downgraded Brown & Brown (BRO) to Equal Weight from Overweight with a price target of $101, down from $104. The company’s organic growth will be below peers in the near-term given its over-concentration to the south and property, the firm tells investors in a research note.